Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 18/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21823356 | 0.89 | FPR2 (0.50) | FPR2IRAK4PDE4B | |
| SCHEMBL31096024 | 0.89 | FPR2 (0.53) | FPR2PDE4BSMN1; SMN2 | |
| SCHEMBL21823714 | 0.89 | FPR2 (0.53) | FPR2PDE4BSMN1; SMN2 | |
| SCHEMBL21823604 | 0.80 | FPR2 (0.50) | FPR2PDE4B | |
| SCHEMBL31096087 | 0.80 | FPR2 (0.50) | FPR2PDE4B | |
| SCHEMBL21823732 | 0.74 | FPR2 (0.51) | FPR2PDE4B | |
| SCHEMBL31095961 | 0.74 | FPR2 (0.51) | FPR2PDE4B | |
| SCHEMBL21823708 | 0.74 | ALDH1A1 (0.48) | FPR2PDE4BSMN1; SMN2 | |
| SCHEMBL21823749 | 0.74 | FPR2 (0.51) | FPR2PDE4B | |
| SCHEMBL21823411 | 0.74 | FPR2 (0.48) | FPR2PDE4BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3861001-A1 | BORON CONTAINING PDE4 INHIBITORS | Pfizer Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166177-A | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2020070651-A1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | FPR2 4123/4885IRAK4 316/4885PDE4B 1/4885 |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | FPR2 3899/4885IRAK4 502/4885PDE4B 1/4885 |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | FPR2 3899/4885IRAK4 502/4885PDE4B 1/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | FPR2 3899/4885IRAK4 502/4885PDE4B 1/4885 |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PDE4A, PDE4B, PDE12 | FPR2 4073/4885IRAK4 678/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.